Key Insights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed with results

Key Signals

3Total

Not Applicable (1)

P 1 (1)

P 3 (1)

Unknown2

Recruiting2

Clinical Trials (4)

Showing 4 of 4 trials

Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia

A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study

Health Outcomes of Patients With Stable Chronic Disease Managed With a Healthcare Kiosk

Showing all 4 trials